Article ; Online: How do we…consistently provide high-dose granulocyte products for transfusions in neutropenic patients?
2023 Volume 63, Issue 7, Page(s) 1267–1276
Abstract: Background: The therapeutic use of granulocyte transfusions for the treatment of infections in immunocompromised patients has been a controversial practice. Randomized controlled trials suggest that benefit may be provided when a high-dose product, ... ...
| Abstract | Background: The therapeutic use of granulocyte transfusions for the treatment of infections in immunocompromised patients has been a controversial practice. Randomized controlled trials suggest that benefit may be provided when a high-dose product, defined as providing a dose of at least 0.6 × 10 Methods: A retrospective chart review was performed for apheresis granulocyte donations collected between 2018 and 2021 following implementation of combined G-CSF and dexamethasone donor stimulation at our institution. Data collected includes donor demographics, G-CSF administration timeline, pre-collection cell counts, product yields, donor adverse events, and post-transfusion ANC increments. Results: A total of 269 granulocyte units were collected from 184 unique donors. The median neutrophil yield (ANC) following G-CSF implementation was 7.5 × 10 Discussion: In order to properly assess the effectiveness of granulocyte transfusions in patients, it is necessary to ensure that the products being transfused contain an adequate granulocyte dose. This study demonstrates that the combination of G-CSF and dexamethasone donor stimulation, followed by apheresis granulocyte collection, is safe and can reliably yield a high-dose product. Consistent production of high-dose units allows for better assessment of patient outcomes by reducing dosage variability. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adult ; Humans ; Retrospective Studies ; Granulocytes ; Neutrophils ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Dexamethasone/therapeutic use | |||||
| Chemical Substances | Granulocyte Colony-Stimulating Factor (143011-72-7) ; Dexamethasone (7S5I7G3JQL) | |||||
| Language | English | |||||
| Publishing date | 2023-06-26 | |||||
| Publishing country | United States | |||||
| Document type | Case Reports | |||||
| ZDB-ID | 208417-x | |||||
| ISSN | 1537-2995 ; 0041-1132 | |||||
| ISSN (online) | 1537-2995 | |||||
| ISSN | 0041-1132 | |||||
| DOI | 10.1111/trf.17461 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 284: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.